Tumors that are negative for expression of ER and PR and for amplification of HER2 expression are termed triple negative breast cancers (TNBC) and display a more aggressive phenotype that is not amenable to steroid hormone/HER2-based targeted therapies and has a worse prognosis than receptor positive cancer [1]. Here, ERBB2 is linked to triple-negative breast carcinoma.